Biotech Values

[dewophile]

It’s nice to see the VKTX efficacy touted by a competitor relative to MDGL. And there is no evidence of toxicity w the VKTX compound *to date*. But these are drugs given chronically so it’s a theoretical risk w larger and longer studies that investors may want to be aware. This is obviously coming from a competitor that is years behind who is trying to pitch a case for their own compound so context is important.
The core inhibitor is interesting in that it shows this mechanism could lead to lower hep surface antigen and the Covid program is active across other coronaviruses so all 3 programs has an angle but certainly face uphill battles as very late arrivals which is why the valuation is de minimus